[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595246":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":43,"collaborators":11,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":11,"eligibilityCriteria":51,"healthyVolunteers":48,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":11,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":11,"overallStatus":29,"whyStopped":11,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Beijing Children's Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"treatment group","EXPERIMENTAL",null,[13],"Drug: recombinant humanized anti-CD25 monoclonal antibody",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","recombinant humanized anti-CD25 monoclonal antibody","For children at high risk of GVHD, one of the following conditions must be met (haploidentical donors must meet one condition, while unrelated donors must meet two conditions):\n\n1. The donor is ≥40 years old;\n2. The donor is an unrelated donor with ≥1 locus mismatch, a haploidentical female donor, or collateral consanguinity (e.g., cousin, uncle\u002Faunt);\n3. Pre-transplant CD3 count ≥4 x 10\\^8\u002Fkg;\n4. The primary disease is in an HLH (hemophagocytic lymphohistiocytosis) flare or active disease phase;\n5. ATG (or biologically equivalent doses of ATLG \\[1:2\\] or ALG \\[1:20\\]) \\\u003C10mg\u002Fkg. Combining recombinant anti-CD25 humanized monoclonal antibody with conventional pretreatment regimen, before peripheral blood stem cell transfusion (i.e. 0d) and+3d, 1mg\u002Fkg，\\\u003C40kg the maximum dose should not exceed25mg\u002Fdose, ≥40kg 1mg\u002Fkg, and the maximum dose should not exceed 50mg\u002Fdose.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Jun Yang","CONTACT","+86 01059612403","yangjundabby@outlook.com",[27],{"facility":28,"status":29,"city":30,"state":11,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Beijing Children's Hospital Capital Medical University","RECRUITING","Beijing","100045","China","CN",{"type":35,"coordinates":36},"Point",[37,38],116.39723,39.9075,{"lat":38,"lon":37},[41],{"name":22,"role":23,"phone":42,"phoneExt":11,"email":25},"+8601059612403",{"type":44,"investigatorFullName":22,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Doctor","100595246","phase-4-improved-myeloablative-allogeneic-hematopoietic-stem-cell-transplantation-protocol-for-the-treatment-of-epstein-barr-virus-tnk-lymphoproliferative-disease-ebv-tnk-lpd-and-prevention-of-post-transplant-graft-versus-host-disease-100595246",false,"NCT07029958","Improved Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Protocol for the Treatment of Epstein Barr Virus T\u002FNK Lymphoproliferative Disease (EBV-T\u002FNK LPD) and Prevention of Post Transplant Graft-versus-host Disease","Inclusion Criteria:\n\n* Meet the diagnosis of EBV-T\u002FNK lymphoproliferative disease (EBV-T\u002FNK LPD) according to the ICC2022 diagnostic criteria\n* Plan to undergo allogeneic hematopoietic stem cell transplantation (allo HSCT) in our hospital\n* Age ≤ 18 years old\n* Sign informed consent form\n* Meet one of the following conditions (haploid donors must meet one of the above conditions, unrelated donors must meet two of the above conditions): ① donor age≥40 years old; ② The donor source is unrelated donor or haplotype related female or collateral donor (brother sisters, etc.) with ≥ 1 point mismatch; ③ CD3≥4 x 10 \\^ 8\u002Fkg before transplantation; ④ The primary disease is in an HLH (hemophagocytic lymphohistiocytosis) flare or active disease phase; ⑤ ATG (or ATLG (1:2)\u002FALG (1:20) equivalent dose)\\\u003C10mg\u002Fkg\n\nExclusion Criteria:\n\n* The expected survival period for multiple organ failure is no more than 3 months\n* Not signing the informed consent form","ALL","0 Years","18 Years",{"count":56,"type":57},48,"ESTIMATED","INTERVENTIONAL",[60],"PHASE4","To investigate whether the addition of recombinant humanized anti-CD25 monoclonal antibody to the conventional EBV-T\u002FNK LPD conditioning regimen can prevent acute and chronic GVHD after transplantation, improve the severity of GVHD and have a corresponding impact on other related post-transplant complications such as poor engraftment, thrombotic microvascular disease, early EBV reactivation and relapse.",[63],"EBV-T\u002FNK LPD","2025-06-12",{"date":66,"type":67},"2025-06-19","ACTUAL",{"date":69,"type":67},"2024-11-12",{"date":71,"type":57},"2029-10-30",{"name":5,"class":6},1]